BR112016002709A2 - queratinas como biomarcadores para câncer cervical e sobrevivência - Google Patents

queratinas como biomarcadores para câncer cervical e sobrevivência

Info

Publication number
BR112016002709A2
BR112016002709A2 BR112016002709A BR112016002709A BR112016002709A2 BR 112016002709 A2 BR112016002709 A2 BR 112016002709A2 BR 112016002709 A BR112016002709 A BR 112016002709A BR 112016002709 A BR112016002709 A BR 112016002709A BR 112016002709 A2 BR112016002709 A2 BR 112016002709A2
Authority
BR
Brazil
Prior art keywords
cervical cancer
survival
keratins
biomarkers
current disclosure
Prior art date
Application number
BR112016002709A
Other languages
English (en)
Inventor
I Chen Emily
R Shroyer Kenneth
F Escobar-Hoyos Luisa
Original Assignee
Univ New York State Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ New York State Res Found filed Critical Univ New York State Res Found
Publication of BR112016002709A2 publication Critical patent/BR112016002709A2/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57411—Specifically defined cancers of cervix
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4742—Keratin; Cytokeratin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

resumo “queratinas como biomarcadores para cancer cervical e sobrevivência” a corrente revelação provê métodos para detectar e analisar a expressão de krt4 e krt17 em uma amostra obtida a partir de um paciente teste. a corrente revelação se refere a métodos e kits para identificar um paciente mamífero com câncer cervical ou lesões não cancerosas da cérvice. a corrente revelação ainda provê métodos e kits para determinar a probabilidade de sobrevivência ou resultado do tratamento de um paciente tendo câncer cervical por determinar o nível de expressão do krt17 em uma amostra.
BR112016002709A 2013-08-08 2014-08-08 queratinas como biomarcadores para câncer cervical e sobrevivência BR112016002709A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361863671P 2013-08-08 2013-08-08
US201361865750P 2013-08-14 2013-08-14
PCT/US2014/050267 WO2015021346A1 (en) 2013-08-08 2014-08-08 Keratins as biomarkers for cervical cancer and survival

Publications (1)

Publication Number Publication Date
BR112016002709A2 true BR112016002709A2 (pt) 2017-09-12

Family

ID=52461952

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016002709A BR112016002709A2 (pt) 2013-08-08 2014-08-08 queratinas como biomarcadores para câncer cervical e sobrevivência

Country Status (5)

Country Link
US (3) US20160187341A1 (pt)
EP (1) EP3030679A4 (pt)
CN (2) CN110527728A (pt)
BR (1) BR112016002709A2 (pt)
WO (1) WO2015021346A1 (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110527728A (zh) * 2013-08-08 2019-12-03 纽约州州立大学研究基金会 作为子宫颈癌和存活期的生物标记物的角蛋白
WO2017075174A1 (en) * 2015-10-29 2017-05-04 The Research Foundation For The State University Of New York Keratin 17 as a prognostic marker for pancreatic cancer
KR101986175B1 (ko) * 2016-07-14 2019-06-07 경희대학교 산학협력단 케라틴을 포함하는 항암용 조성물
US11360092B2 (en) 2016-08-05 2022-06-14 The Research Foundation For The State University Of New York Keratin 17 as a biomarker for bladder cancer
CN112014562A (zh) * 2020-08-14 2020-12-01 武汉大学 用于免疫检查点pd-1/pd-l1动态监测的标记物组合、方法及系统

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5858683A (en) * 1996-08-30 1999-01-12 Matritech, Inc. Methods and compositions for the detection of cervical cancer
JP2006514823A (ja) * 2002-08-20 2006-05-18 ミレニアム ファーマスーティカルズ インク 子宮頸癌の同定、評価、予防および治療を行うための組成物、キットおよび方法
EP2293069A3 (en) * 2004-03-24 2011-09-21 Tripath Imaging, Inc. Methods and compositions for the detection of cervical disease
US20060154275A1 (en) * 2004-12-02 2006-07-13 The Board Of Trustees Of The Leland Stanford Junior University Regulated genes in cervical cancer
US20120231468A1 (en) * 2008-03-19 2012-09-13 Board Of Trustees Of The University Of Illinois Rna from cytology samples to diagnose disease
GB0922437D0 (en) * 2009-12-22 2010-02-03 Cancer Rec Tech Ltd Hypoxia tumour markers
US8859468B2 (en) * 2010-03-12 2014-10-14 The Johns Hopkins University Hypermethylation biomarkers for detection of cervical cancer
US20120225954A1 (en) * 2010-09-05 2012-09-06 University Health Network Methods and compositions for the classification of non-small cell lung carcinoma
EP2663672A1 (en) * 2011-01-11 2013-11-20 University Health Network Prognostic signature for oral squamous cell carcinoma
SE536352C2 (sv) * 2011-10-24 2013-09-03 Chundsell Medicals Ab Markörgener för klassificiering av prostatacancer
EP2909341A2 (en) * 2012-10-18 2015-08-26 Oslo Universitetssykehus HF Biomarkers for cervical cancer
CN110527728A (zh) * 2013-08-08 2019-12-03 纽约州州立大学研究基金会 作为子宫颈癌和存活期的生物标记物的角蛋白
US20170082632A1 (en) * 2014-05-16 2017-03-23 The Research Foundation For The State University Of New York Keratin 17 as a biomarker for head and neck cancers
US20160025729A1 (en) * 2014-07-25 2016-01-28 OncoGenesis Inc. Systems And Methods For Early Detection Of Cervical Cancer By Multiplex Protein Biomarkers
WO2016141269A1 (en) * 2015-03-05 2016-09-09 The Research Foundation For The State University Of New York Keratin 17 as a diagnostic and therapeutic target for cancer
EP3389481A4 (en) * 2015-12-18 2019-05-22 Clear Gene, Inc. PROCESSES, COMPOSITIONS, KITS AND DEVICES FOR FAST LANALYSIS OF BIOLOGICAL MARKERS
US11360092B2 (en) * 2016-08-05 2022-06-14 The Research Foundation For The State University Of New York Keratin 17 as a biomarker for bladder cancer
CN110290794A (zh) * 2016-11-01 2019-09-27 纽约州州立大学研究基金会 5-卤代尿嘧啶修饰的微rna及其在癌症治疗中的用途
GB201902653D0 (en) * 2019-02-27 2019-04-10 Univ Oxford Innovation Ltd High-grade serous ovarian carcinoma (HGSOC)

Also Published As

Publication number Publication date
US20230204583A1 (en) 2023-06-29
CN105899673A (zh) 2016-08-24
WO2015021346A1 (en) 2015-02-12
US20160187341A1 (en) 2016-06-30
US20180059112A1 (en) 2018-03-01
CN110527728A (zh) 2019-12-03
EP3030679A1 (en) 2016-06-15
EP3030679A4 (en) 2017-04-12
CN105899673B (zh) 2019-09-13

Similar Documents

Publication Publication Date Title
ES2656962T3 (es) Métodos para evaluar la receptividad del endometrio de una paciente
AR095363A1 (es) Biomarcadores y métodos para el tratamiento de condiciones relacionadas con pd-1 y pd-l1
BR112014000965B8 (pt) Método, aparelho e meio de armazenamento não transitório
MX2018008421A (es) Métodos para tratar cáncer y el uso de biomarcadores como predictor de sensibilidad clínica a terapias.
BR112016002709A2 (pt) queratinas como biomarcadores para câncer cervical e sobrevivência
BR112018069849A2 (pt) kit, dispositivo e método para a detecção de câncer pancreático precoce ou de lesão precursora do câncer pancreático
MX2021006791A (es) Metodos y composiciones para detectar proteinas mal plegadas.
NZ607282A (en) Method for using gene expression to determine prognosis of prostate cancer
BR112015000018A2 (pt) método e aparelho para determinar as contagens de células brancas do sangue
BR112013003391A2 (pt) biomarcadores de câncer pancreático e usos dos mesmos
EA201500080A1 (ru) Способ in vitro диагностирования и мониторинга рака
NZ621733A (en) Lung cancer biomarkers and uses thereof
BR112017006315A2 (pt) agente terapêutico, uso de um agente terapêutico, métodos in vitro para determinar se um sujeito com melanoma tem um risco maior de desenvolver metástase, de determinação de um regime de tratamento para um sujeito que sofre de melanoma, de tratamento de um sujeito que sofre de melanoma, ensaio in vitro para predizer o risco aumentado de metástase e kits
NZ578283A (en) Proteomic profiling method useful for condition diagnosis and monitoring, composition screening, and therapeutic monitoring
CR20130657A (es) Ensayo de lisiloxidasa-homólogo 2 y métodos de uso del mismo
PE20170298A1 (es) Composiciones y metodos relacionados con el diagnostico del cancer de prostata
AR080361A1 (es) Identificacion, evaluacion y terapia de canceres con resistencia innata o adquirida a inhibidores de quinasa del linfoma anaplasico (alk)
AR100169A1 (es) Tratamiento del cáncer
BR112018073214A2 (pt) métodos para a previsão do risco de recorrência da fibrilação atrial, para o diagnóstico de fibrilação atrial em um indivíduo, para o monitoramento de uma terapia e para a classificação da fibrilação e utilizações do biomarcador
BR112018011224A2 (pt) processo de avaliação do risco de complicações nos pacientes que apresentam uma síndrome da resposta inflamatória sistêmica (sirs)
BR112017011026A2 (pt) métodos analíticos e arranjos para uso nos mesmos
EA201691497A1 (ru) Способы детектирования и количественного определения имитаторов циркулирующих опухолевых клеток
MX360479B (es) Anticuerpos contra microbioma, factores de estres y marcadores de mastocitos como marcadores de diagnostico para ibs.
BR112014031957A2 (pt) bag3 como soro bioquímico e marcador de tecido
WO2015189591A3 (en) Method and arrays for use in diagnosing early breast cancer

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]